ArticleRespirology case reports2026
Six-Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Six-Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics.Respirology case reports · 2026Article
- New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic chronic eosinophilic pneumonia (ICEP) often relapses upon corticosteroid tapering. Biologics targeting interleukin-5 (IL-5) are effective, but optimal dosing intervals remain unclear. We report a case of relapsing ICEP in a patient in her 50s. Mepolizumab, an IL-5 ligand blocker, failed to maintain remission, with clinical relapse occurring 4 months after initiation. Switching to benralizumab, an interleukin-5 receptor blocker, induced rapid and deep eosinophil depletion. For optimising dosing, treatment was temporarily withheld, revealing a prolonged remission duration of 8 months before eosinophil recovery and clinical relapse. Based on these kinetics, a 6-monthly benralizumab maintenance strategy was established. The patient has remained relapse-free with zero eosinophils for over 2 years under this biannual regimen. This case suggests that benralizumab offers superior durability compared to mepolizumab in CEP due to deep depletion, enabling an extended, cost-effective dosing interval guided by individual eosinophil recovery kinetics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.